{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T14:17:20Z","timestamp":1696688240328},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"10","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A novel study design comparing results from a phase II trial with those from a prior phase III trial shows that a daratumumab-based regimen is more effective in ultra-high-risk myeloma than a conventional drug combination. However, it is unclear whether this approach can be applied to other contexts and forms of cancer.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2023-0057","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T12:50:36Z","timestamp":1691671836000},"page":"OF1-OF1","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Might Myeloma Trial Point to Novel Study Approach?"],"prefix":"10.1158","volume":"13","member":"1086","published-online":{"date-parts":[[2023,8,10]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-NB2023-0057\/728401\/Might-Myeloma-Trial-Point-to-Novel-Study-Approach","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/13\/10\/OF1\/729375\/Might-Myeloma-Trial-Point-to-Novel-Study-Approach","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/13\/10\/OF1\/729375\/Might-Myeloma-Trial-Point-to-Novel-Study-Approach","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T16:31:48Z","timestamp":1696609908000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/13\/10\/OF1\/729375\/Might-Myeloma-Trial-Point-to-Novel-Study-Approach"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":0,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,8,10]]},"published-print":{"date-parts":[[2023,10,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2023-0057","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}